Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Foresee Pharmaceuticals Co's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$1,627.7 Mil. Foresee Pharmaceuticals Co's average total tangible assets for the quarter that ended in Mar. 2026 was NT$1,517.8 Mil. Therefore, Foresee Pharmaceuticals Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 107.24%.
The historical rank and industry rank for Foresee Pharmaceuticals Co's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:6576'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -104.07 Med: -61.48 Max: -12.15
Current: -12.15
During the past 12 years, Foresee Pharmaceuticals Co's highest Return-on-Tangible-Asset was -12.15%. The lowest was -104.07%. And the median was -61.48%.
ROCO:6576's Return-on-Tangible-Asset is ranked worse than 79.17% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.05
vs ROCO:6576: -12.15
Foresee Pharmaceuticals Co (ROCO:6576) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Foresee Pharmaceuticals Co Return-on-Tangible-Asset Related Terms
Foresee Pharmaceuticals Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foresee Pharmaceuticals Co Return-on-Tangible-Asset Chart
ROCO:6576 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 107.24% mean?
Foresee Pharmaceuticals Co (ROCO:6576) has a Return-on-Tangible-Asset of 107.24% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Foresee Pharmaceuticals Co and its competitors. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #798 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 79.2%.
Is Foresee Pharmaceuticals Co's Return-on-Tangible-Asset too high?
Foresee Pharmaceuticals Co's current Return-on-Tangible-Asset is 107.24%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.05. Foresee Pharmaceuticals Co's value of 107.24% is 3416.1% above this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #798 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #798 out of 1008 companies for Return-on-Tangible-Asset. This places Foresee Pharmaceuticals Co in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.05. Foresee Pharmaceuticals Co's value of 107.24% is 3416.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.05, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current Return-on-Tangible-Asset of 107.24% is 3416.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Foresee Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current Return-on-Tangible-Asset is 107.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Fairly Valued. The stock's GF Value™ is NT$84.18, compared to a current price of NT$79.70 — trading 5.3% below its estimated fair value. The current Return-on-Tangible-Asset is 107.24% and 3416.1% above the Drug Manufacturers industry median of 3.05. Foresee Pharmaceuticals Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current Return-on-Tangible-Asset is 107.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$79.70 is trading 5.3% below its estimated GF Value™ of NT$84.18.
GuruFocus considers Foresee Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for ROCO:6576:
Return-on-Tangible-Asset: 107.24%
GF Value™: NT$84.18 vs. price of NT$79.70 (5.3% below fair value)
Industry Position: 3416.1% above the Drug Manufacturers median (#798 of 1008)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
65GF Score
Get the complete analysis for ROCO:6576
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
